GENETICALLY ENGINEERED HSV 1 IN MALIGNANT GLIOMA

恶性胶质瘤是一种几乎一致致命的中枢神经系统癌症，对传统治疗方式很难奏效。一种有希望的新方法是使用基因工程的、有条件地复制的单纯疱疹病毒(HSV)，在传统疗法之后杀死剩余的肿瘤细胞。G207是一种重组HSV，缺乏在正常脑细胞中复制所必需的基因。G207已被证明在治疗小鼠模型中的人类和啮齿动物肿瘤方面都是有效的。在Aotus nancymai(Aotus Nancymai)的脑内接种后，安全性已被确立。我们推测，G207，一种基因工程的HSV-1，将是安全的，并有可能用于治疗恶性胶质瘤患者，这些患者在MRI上有进展性疾病的证据，尽管接受了常规手术和/或活检和外放射治疗。给药方式将是立体定向将病毒接种到肿瘤的增强区域。

Malignant glioma is a nearly uniformly lethal cancer of the central nervous system that is largely refractory to conventional modalities of therapy. One promising new approach is the use of a genetically engineered, conditionally replicating herpes simplex virus (HSV) following conventional therapy to kill remaining tumor cells. G207 is a recombinant HSV lacking genes essential for replication in normal brain cells. G207 has been shown to be efficacious in the treatment of both human and rodent tumors in murine models. Safety has been established following intracranial inoculation in the Aotus monkey (Aotus nancymai). We hypothesize that G207, a genetically-engineered HSV-1, will be safe and potentially useful for the treatment of patients with malignant gliomas who have evidence of progressive disease on MRI despite treatment with conventional surgery and/or biopsy and external beam radiation. The mode of administration will be stereotactic inoculation of virus into an enhancing region of the tumor.